Kare Schultz - Feb 8, 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
President and CEO, Director
Signature
/s/ Dov Bergwerk as attorney-in-fact for Kare Schultz
Stock symbol
TEVA
Transactions as of
Feb 8, 2022
Transactions value $
$0
Form type
4
Date filed
2/10/2022, 03:12 PM
Previous filing
Nov 3, 2021
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +26.9K +2.58% 1.07M Feb 9, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -26.9K -100% $0.00* 0 Feb 9, 2022 Ordinary Shares 26.9K Direct F2, F3
transaction TEVA Restricted Share Units Award $0 +163K $0.00 163K Feb 8, 2022 Ordinary Shares 163K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted share units were granted on February 9, 2018, with 26,867 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.
F4 Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.